david
corti
elisabetta
cameroni
barbara
guarino
nicol
l
kallewaard
qing
zhu
antonio
lanzavecchia
monoclon
antibodi
revolution
treatment
sever
human
diseas
includ
cancer
autoimmun
inflammatori
condit
repres
new
frontier
treatment
infecti
diseas
last
decad
new
method
allow
effici
interrog
human
antibodi
repertoir
influenza
immun
individu
isol
sever
monoclon
antibodi
capabl
deal
high
variabl
influenza
virus
provid
comprehens
overview
specif
antivir
immunolog
mechan
action
develop
clinic
broadli
reactiv
monoclon
antibodi
influenza
b
virus
influenza
virus
respons
annual
epidem
entail
signific
morbid
mortal
particularli
elderli
immunecompromis
individu
hemagglutinin
glycoprotein
ha
main
target
influenza
b
neutral
antibodi
respons
infect
vaccin
monom
trimer
ha
compos
two
polypeptid
gener
proteolyt
cleavag
precursor
globular
head
ha
bind
sialic
acid
residu
target
cell
stem
region
mediat
low
phtrigger
fusion
viral
cellular
membran
endosom
sixteen
subtyp
ha
two
ha
analog
identifi
bat
cluster
two
group
group
compris
group
compris
current
circul
human
virus
belong
group
subtyp
deriv
pandem
group
subtyp
deriv
pandem
subtyp
endem
human
could
reemerg
other
caus
episod
zoonot
infect
sustain
humantohuman
transmiss
group
group
subtyp
influenza
b
virus
exist
singl
type
repres
two
cocircul
antigen
distinct
lineag
defin
prototyp
virus
byamagata
second
viral
glycoprotein
neuraminidas
na
mushroomshap
tetram
act
receptordestroy
enzym
remov
sialic
acid
residu
surfac
infect
cell
therebi
allow
releas
spread
bud
virion
nine
subtyp
na
cluster
two
group
group
group
na
enzymat
site
influenza
b
virus
target
four
approv
antiinfluenza
drug
oseltamivir
peramivir
laninamivir
zanamivir
protein
influenza
b
orthologu
homotetram
function
proton
channel
low
ph
endosom
trigger
uncoat
viral
ribonucleoprotein
rnp
complex
poorli
express
virion
abundantli
display
surfac
infect
cell
specif
inhibitor
amantadin
rimantandin
block
infect
prevent
rnp
uncoat
releas
cytoplasm
howev
clinic
use
drug
current
recommend
due
widespread
resist
current
standard
care
vaccin
strategi
suboptim
treat
prevent
sever
influenza
b
viru
infect
inde
trival
tetraval
influenza
vaccin
partial
effect
elderli
immunocompromis
individu
case
select
strain
match
circul
addit
antivir
na
inhibitor
blocker
limit
efficaci
sever
case
influenza
infect
administ
within
hour
symptom
onset
may
select
resist
clinic
studi
patient
sever
viral
pneumonia
caus
viral
sarscov
pandem
virus
zoonot
influenza
viru
shown
therapeut
benefit
use
convalesc
plasma
especi
administ
earli
symptom
onset
howev
poor
suppli
convalesc
plasma
low
antibodi
titer
hamper
util
approach
identif
last
decad
sever
broadli
neutral
antibodi
influenza
b
virus
isol
plasma
cell
memori
b
cell
influenzainfect
influenzavaccin
individu
repres
safe
afford
altern
use
patientderiv
convalesc
plasma
inde
recent
data
suggest
passiv
immun
use
broadli
neutral
monoclon
antibodi
might
repres
viabl
approach
prophylaxi
therapi
might
complement
substitut
current
vaccin
antivir
review
current
literatur
broadli
neutral
antibodi
influenza
virus
discuss
mechan
action
clinic
develop
extens
variabl
globular
head
ha
target
antibodi
limit
breadth
antibodi
recogn
antigen
similar
strain
within
singl
ha
subtyp
prone
select
escap
mutant
nonetheless
monoclon
antibodi
target
sever
isol
within
subtyp
influenza
eg
describ
similar
class
antihead
antibodi
multilineag
neutral
influenza
b
virus
also
report
includ
target
epitop
overlap
receptor
bind
site
ha
direct
epitop
base
head
swem
l
et
al
us
sialic
acid
bind
pocket
ha
repres
conserv
site
rare
antibodi
precis
target
site
describ
howev
neutral
activ
antibodi
scatter
multipl
group
group
virus
typic
fraction
strain
within
subtyp
neutral
figur
ha
stem
repres
rel
conserv
region
involv
process
viral
fusion
consequ
antibodi
direct
stem
region
ha
often
capabl
heterosubtyp
neutral
across
one
influenza
group
tabl
gener
antibodi
target
stem
region
ha
rare
compar
target
variabl
region
globular
head
frequent
antistem
heterosubtyp
antibodi
group
virus
found
elicit
vaccin
infect
virus
xray
structur
analysi
three
antibodi
reveal
target
similar
epitop
ha
stem
contact
conserv
residu
hydrophob
pocket
helix
region
group
neutral
antibodi
less
frequent
possibl
due
shield
ha
stem
epitop
conserv
glycan
inde
solv
structur
group
antibodi
negativestain
electron
microscopi
em
reconstruct
antibodi
indic
bind
region
locat
membraneproxim
base
ha
stem
interestingli
group
virus
region
mask
highli
conserv
glycan
intens
discoveri
campaign
led
identif
rare
group
heterosubtyp
neutral
antibodi
ten
avail
xray
structur
figur
reveal
antibodi
adopt
multipl
bind
modal
cope
high
amino
acid
divers
structur
constraint
pose
presenc
conserv
glycan
despit
restrict
propens
stem
region
mutat
escap
mutant
isol
also
antistem
antibodi
exist
also
support
incomplet
breadth
certain
antistem
antibodi
exampl
lack
bind
human
virus
final
rare
antibodi
shown
bind
sever
influenza
b
virus
test
although
neutral
activ
limit
influenza
breadth
appear
result
high
plastic
bind
site
abl
accommod
recognit
variou
conform
conserv
tryptophan
presenc
influenza
bspecif
glycan
sever
studi
identifi
structur
genet
requir
develop
broadli
neutral
antiha
influenza
antibodi
preferenti
heavi
variabl
vh
gene
usag
presenc
key
somat
mutat
sequenc
signatur
antibodi
cdr
note
polyreact
group
antistem
antibodi
propos
result
b
cell
counterselect
vivo
knowledg
valuabl
guid
design
univers
influenza
vaccin
besid
ha
viral
envelop
protein
na
propos
target
broadli
neutral
antibodi
anim
model
shown
nadirect
antibodi
correl
reduc
sever
diseas
epidemiolog
studi
human
suggest
role
na
immun
reduc
last
viral
shed
symptom
recent
univers
epitop
na
conserv
among
influenza
b
strain
identifi
rabbit
monoclon
antibodi
rais
region
provid
group
heterosubtyp
protect
challeng
mice
highli
conserv
extracellular
domain
attract
target
vaccin
design
antibodi
therapeut
antibodi
influenza
ha
directli
neutral
influenza
viru
level
entri
fusion
proteolyt
cleavag
name
block
bind
sialic
acid
residu
surfac
target
cell
b
inhibit
endosom
viral
fusion
c
prevent
releas
progeni
virion
infect
cell
inhibit
extracellular
proteolyt
cleavag
ha
mode
viral
neutral
depend
site
recogn
trimer
ha
thu
antihead
antibodi
work
primarili
inhibit
viral
entri
detect
classic
hemagglutin
inhibit
assay
hai
antistem
antibodi
block
bind
sialic
acid
inact
hai
instead
prevent
endosom
epitop
specif
breadth
influenza
b
heterosubtyp
neutral
antibodi
breadth
reactiv
influenza
heterosubtyp
neutral
antibodi
group
upper
group
lower
subtyp
deriv
publish
data
see
tabl
viral
fusion
viral
bud
ha
cleavag
activ
figur
addit
mechan
action
beyond
viral
neutral
contribut
vivo
protect
inde
broadli
reactiv
antibodi
direct
either
ha
head
stem
lack
vitro
neutral
activ
show
vivo
efficaci
prophylact
set
multipl
studi
last
decad
illustr
complex
antibodydepend
vivo
protect
shown
involv
addit
direct
mechan
describ
also
indirect
ie
fcdepend
mechan
action
mediat
interact
fc
portion
fcgr
immun
cell
complement
importantli
fcdepend
effector
function
recruit
influenzaspecif
antibodi
includ
antiha
antina
fcgrdepend
mechan
assess
vitro
measur
antibodydepend
cytotox
mediat
nk
cell
adcc
antibodydepend
cellular
cytotox
complement
cdc
complementdepend
cytotox
well
antibodydepend
cellular
phagocytosi
adcp
contribut
fcfcgr
interact
vivo
demonstr
use
differ
fc
format
antibodi
influenza
viru
infect
wild
type
mice
transgen
mice
express
full
array
human
fcgr
lack
individu
mous
mfcgr
studi
reveal
fcmediat
effector
function
activ
fcgr
contribut
vivo
prophylact
efficaci
antistem
antibodi
low
antibodi
dose
high
antibodi
dose
protect
primarili
mediat
viru
neutral
gener
agreement
antistem
antibodi
potent
induc
adcc
vitro
requir
fcgr
interact
optim
vivo
protect
antihead
antibodi
role
fcmediat
effector
function
still
controversi
role
fcdepend
effector
mechan
mediat
antibodydepend
vivo
protect
import
practic
implic
given
possibl
enhanc
function
glycoengin
mutat
fc
portion
even
combin
two
consensu
fact
antistem
antibodi
effici
engag
fcr
compar
antihead
structur
basi
differ
clear
although
may
relat
membraneproxim
engag
fcr
interestingli
recent
studi
suggest
adcc
influenzainfect
cell
enhanc
accessori
interact
ha
infect
cell
sialic
acid
motif
nk
cell
may
stabil
immunolog
synaps
thu
increas
avid
target
nk
cell
find
consist
observ
antihead
antibodi
induc
adcc
interfer
bind
sialic
acid
therefor
haineg
convers
hai
posit
antihead
antibodi
block
bind
sialic
acid
less
effect
promot
adcc
interestingli
interact
ha
nk
cell
found
depend
sialyl
nk
cell
receptor
namedi
remov
sialic
acid
shown
repres
immuneevas
mechan
influenza
virus
reciproc
inhibit
na
activ
oseltamivir
shown
boost
recognit
kill
infect
cell
find
might
explain
antivir
strategi
mechan
antivir
protect
antiha
antibodi
direct
mechan
depend
fab
engag
includ
antihead
antibodi
red
block
viral
entri
target
receptor
bind
site
ha
indirectli
project
fc
receptor
bind
site
b
antistem
antibodi
blue
interfer
phdriven
ha
rearrang
block
process
viral
fusion
endosom
c
antihead
antistem
antibodi
inhibit
releas
bud
virion
infect
cell
antistem
antibodi
imped
cleavag
extracellular
proteas
therebi
block
proteolyt
cleavag
ha
fusogen
form
indirect
mechan
depend
fc
engag
includ
antibodydepend
cellular
cytotox
adcc
antibodydepend
cellular
phagocytosi
adcp
complementdepend
cytotox
cdc
antibodi
perform
stronger
fcdepend
mechan
depict
full
line
arrow
antibodi
perform
weaker
depict
dot
line
arow
synergist
addit
effect
observ
anim
treat
antistem
antibodi
presenc
nainhibitor
antibodydepend
recruit
virion
contribut
directli
antibodymedi
viru
neutral
steric
hindranc
effect
wherea
recruit
infect
cell
activ
complement
cascad
lead
kill
cdc
interestingli
stemspecif
antibodi
particularli
effect
induc
cdc
possibl
due
recruit
complement
cascad
proxim
cell
membran
opsonophagocytosi
repres
anoth
import
fcdepend
mechan
antibodymedi
clearanc
virion
infect
cell
adcp
mainli
alveolar
macrophag
recent
studi
show
antibodi
unabl
induc
adcc
cdc
highli
effect
adcp
suggest
antibodi
phagocytosi
could
major
mechan
protect
influenc
epitop
specif
adcp
remain
establish
import
fcmediat
effector
function
vivo
well
illustr
efficaci
studi
use
antibodi
antibodi
neutral
viru
infect
vitro
show
signific
therapeut
efficaci
vivo
bind
protein
express
surfac
virusinfect
cell
import
phagocytosi
alveolar
macrophag
vivo
immun
protect
antibodi
demonstr
role
adcc
cdc
remain
controversi
simultan
occurr
differ
antivir
mechan
list
precis
correl
vitro
activ
vivo
protect
addit
crosstalk
among
serum
antibodi
vari
specif
could
determin
magnitud
direct
viral
neutral
fc
receptormedi
effector
function
studi
also
suggest
role
antibodi
enhanc
diseas
sever
young
pig
polyclon
nonneutr
antibodi
induc
enhanc
respiratori
diseas
defin
vaccineassoci
enhanc
respiratori
diseas
vaerd
anoth
studi
immun
complex
format
preexist
nonneutr
antibodi
consequ
deposit
link
tissu
patholog
sever
ill
individu
infect
pandem
viru
viru
despit
difficulti
draw
conclus
studi
analyz
effect
polyclon
antibodi
respons
influenza
infect
enhanc
respiratori
diseas
remain
potenti
concern
develop
antivir
antibodi
therapeut
current
investig
multipl
clinic
studi
despit
advanc
vaccin
smallmolecul
antivir
therapeut
fda
approv
drug
use
individu
sever
influenza
requir
hospit
although
na
inhibitor
use
offlabel
popul
effect
limit
highlight
unmet
medic
need
effect
treatment
influenza
popul
high
risk
morbid
mortal
howev
effect
still
debat
highlight
unmet
medic
need
effect
treatment
influenza
popul
high
risk
morbid
mortal
antibodybas
strategi
prevent
treat
influenza
could
new
altern
countermeasur
influenza
preclin
studi
use
broadli
neutral
antibodi
show
superior
efficaci
longer
therapeut
window
compar
neuraminidas
inhibitor
mice
ferret
suggest
antibodi
therapi
may
provid
signific
clinic
benefit
popul
sever
antiinfluenza
monoclon
antibodi
test
variou
stage
clinic
develop
tabl
antibodi
candid
direct
ha
protein
viru
one
protein
last
year
antibodi
test
small
proofofconcept
human
influenza
challeng
studi
healthi
volunt
experiment
infect
less
virul
strain
viru
therefor
caus
mild
upper
respiratori
symptom
studi
administr
antiha
antibodi
mab
exhibit
signific
reduct
viral
titer
given
subject
advanc
program
primarili
focus
antiha
antibodi
crossreact
group
influenza
virus
either
alon
cocktail
treat
hospit
patient
sever
influenza
visterra
celltrion
antibodi
cocktail
recent
complet
studi
experiment
infect
subject
medimmun
genentech
progress
trial
natur
infect
subject
medimmun
complet
studi
nonhospit
natur
infect
patient
genentech
current
recruit
two
differ
phase
trial
one
natur
infect
uncompl
subject
one
natur
infect
hospit
subject
exu
sever
promis
antibodi
candid
progress
later
stage
develop
hospit
subject
sever
influenza
worth
note
indic
present
signific
challeng
clinic
develop
recent
failur
neuraminidas
inhibitor
peramivir
indic
highlight
challeng
antibodi
also
face
lengthi
recruit
timelin
due
patient
popul
season
viru
uncertainti
pivot
trial
endpoint
show
enhanc
efficaci
standard
care
despit
last
year
effort
design
univers
flu
vaccin
difficult
due
lack
detail
inform
epitop
within
ha
stem
region
key
drive
broad
immun
identif
broadli
neutral
antibodi
subtyp
influenza
virus
provid
basi
design
protect
vaccin
strategi
also
open
door
altern
passiv
immun
approach
prevent
influenza
infect
new
advanc
antibodi
manufactur
capabl
halflif
extens
technolog
altern
deliveri
mechan
use
dna
rna
viru
vector
may
pave
way
costeffect
immunoprophylaxi
use
broadli
neutral
antibodi
paper
particular
interest
publish
within
period
review
highlight
special
interest
outstand
interest
